4.2 Review

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders - First Revision

期刊

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
卷 9, 期 4, 页码 248-312

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/15622970802465807

关键词

Anticonvulsants; antidepressants; antipsychotics; anxiety disorders; anxiolytics; benzodiazepines; cognitive behaviour therapy; evidence-based guidelines; generalized anxiety disorder; obsessive-compulsive disorder; panic disorder; post-traumatic stress disorder; simple phobia; social phobia; SSRI; SNRI; treatment

资金

  1. Glaxo-Smith Kline
  2. Jazz
  3. Lundbeck
  4. Pfizer
  5. Servier
  6. Teva
  7. Wyeth
  8. Abbott BMS
  9. Janssen
  10. Nastech
  11. Neuropharm
  12. AstraZeneca
  13. Bristol-Myers Squibb
  14. CSC
  15. Eli Lilly
  16. Janssen Pharmaceutica
  17. LundbeckNovartis
  18. Organon
  19. Pierre Fabre
  20. Schwabe
  21. Sepracor
  22. Janssen Cilag

向作者/读者索取更多资源

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, World J Biol Psychiatry 3:171), recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo- or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据